Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

Author(s): Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso, Giulia Gustinetti, Laura Sticchi, Bianca Bruzzone, Claudio Viscoli

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 9 , Issue 1 , 2014

Become EABM
Become Reviewer


Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.

Keywords: Cobicistat, elvitegravir, emtricitabine, resistance, side effects, tenofovirDF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [41 - 51]
Pages: 11
DOI: 10.2174/1574891X09666140717102358

Article Metrics

PDF: 77